The lysine acetylation regulators with CNV amplification showed significantly higher expression in cancer cells when compared to normal cells (e.g. KAT2A and ATAT1), while the regulators with CNV deletion showed significantly lower expression (e.g. SIRT6 and SIRT7). This evidence concerns the gene ATAT1 and cancer.